Emerging lines of research evidence
point to a vital role of gut–kidney
axis in the development of hyperuricemia (HUA), which has been identified
as an increasing burden worldwide due to the high prevalence. The
involved crosstalk which links the metabolic and immune-related pathways
is mainly responsible for maintaining the axial homeostasis of uric
acid (UA) metabolism. Nowadays, the urate-lowering drugs only aim
to treat acute gouty arthritis as a result of their controversial
clinical application in HUA. In this study, we established the HUA
model of C57BL/6J mice to evaluate the effectiveness of folic acid
on UA metabolism and further explored the underlying mechanisms. Folic
acid attenuated the kidney tissue injury and excretion dysfunction,
as well as the typical fibrosis in HUA mice. Molecular docking results
also revealed the structure–activity relationship of the folic
acid metabolic unit and the UA transporters GLUT9 and URAT1, implying
the potential interaction. Also, folic acid alleviated HUA-induced
Th17/Treg imbalance and intestinal tissue damage and inhibited the
active state of the TLR4/NF-κB signaling pathway, which is closely
associated with the circulating LPS level caused by the impaired intestinal
permeability. Furthermore, the changes of intestinal microecology
induced by HUA were restored by folic acid, including the alteration
in the structure and species composition of the gut microbiome community,
and metabolite short-chain fatty acids. Collectively, this study revealed
that folic acid intervention exerted improving effects on HUA by ameliorating
gut–kidney axis dysfunction.